Related references
Note: Only part of the references are listed.PolyI: C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors
Roxanne Charlebois et al.
CANCER RESEARCH (2017)
IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
Elizabeth L. McMichael et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Laura Q. M. Chow et al.
CLINICAL CANCER RESEARCH (2017)
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
J. P. Laubach et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response
Birgit Lehmann et al.
SCIENCE IMMUNOLOGY (2017)
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
Maximillian Rosario et al.
CLINICAL CANCER RESEARCH (2016)
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
Valeria Gonzalez-Nicolini et al.
CLINICAL CANCER RESEARCH (2016)
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*
Matt E. Kalaycio et al.
LEUKEMIA & LYMPHOMA (2016)
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy
Carmen Martinez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn et al.
LANCET ONCOLOGY (2016)
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
Julio C. Chavez et al.
LEUKEMIA RESEARCH (2016)
Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker
Joerg U. Schmohl et al.
MOLECULAR THERAPY (2016)
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
Rizwan Romee et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Dinutuximab: A Review in High-Risk Neuroblastoma
Sheridan M. Hoy
TARGETED ONCOLOGY (2016)
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
Stephen R. Adams et al.
NATURE COMMUNICATIONS (2016)
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2016)
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
Emily M. McWilliams et al.
ONCOIMMUNOLOGY (2016)
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Holbrook E. Kohrt et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Jerome Fayette et al.
FRONTIERS IN ONCOLOGY (2016)
Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma
Matthew J. Barth et al.
CLINICAL CANCER RESEARCH (2015)
Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
Suman Mitra et al.
IMMUNITY (2015)
Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
E. Muraro et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology
Michela Croce et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma
Kristen N. Ganjoo et al.
LEUKEMIA & LYMPHOMA (2015)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
Vassiliki Saloura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
Jean-Pierre Delord et al.
EUROPEAN JOURNAL OF CANCER (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells
Sarah S. Donatelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein
Maria C. Ochoa et al.
CANCER RESEARCH (2013)
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Christian A. Gerdes et al.
CLINICAL CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency
Marie Vincent et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
P. Glorius et al.
LEUKEMIA (2013)
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells
Chwee Ming Lim et al.
ONCOIMMUNOLOGY (2013)
Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
Laurent Boissel et al.
ONCOIMMUNOLOGY (2013)
The roles of TGFβ in the tumour microenvironment
Michael Pickup et al.
NATURE REVIEWS CANCER (2013)
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer
N. Steele et al.
BRITISH JOURNAL OF CANCER (2012)
Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells
Xuewen Deng et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2012)
Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor-Targeted Therapy
Atul Bedi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)
Holbrook E. Kohrt et al.
BLOOD (2011)
Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
Suresh Veeramani et al.
BLOOD (2011)
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
William G. Wierda et al.
BLOOD (2011)
TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
Hailing Lu et al.
CLINICAL CANCER RESEARCH (2011)
IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
Kai-Ping Han et al.
CYTOKINE (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
Bruce D. Cheson
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity
Caroline J. Voskens et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
Linda S. Sorkin et al.
PAIN (2010)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma
Jacquelyn A. Hank et al.
CLINICAL CANCER RESEARCH (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
Liat Binyamin et al.
JOURNAL OF IMMUNOLOGY (2008)
TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells
Rossana Trotta et al.
JOURNAL OF IMMUNOLOGY (2008)
Natural killer cell recognition of missing self
Klas Karre
NATURE IMMUNOLOGY (2008)
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells
Tina Mueller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2
Stefania Varchetta et al.
CANCER RESEARCH (2007)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
Khuda D. Khan et al.
CLINICAL CANCER RESEARCH (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
Andreas Lundqvist et al.
CANCER RESEARCH (2006)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
C Imai et al.
BLOOD (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor
T Schirrmann et al.
LEUKEMIA RESEARCH (2005)
FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
SS Farag et al.
BLOOD (2004)
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies:: Analysis of sustained interferon γ production in a subset of patients
R Parihar et al.
CLINICAL CANCER RESEARCH (2004)
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells
S Sivori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies
CI Spiridon et al.
CLINICAL CANCER RESEARCH (2004)
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
O Manches et al.
BLOOD (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
JW Friedberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)